Internal Medicine, Medical Oncology · Clermont, FL
NPI
1841482270
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1340 N Hancock Rd
Clermont, FL, 34711
Phone (352) 394-1150
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.4M
437,342 services
Medicare patients, 2024
1,639
Average age 77
Drug cost, 2024
$12.7M
3,812 prescriptions
Company payments, 2025
$1,744
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ahmed Al-Hazzouri was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 51,510 times for 46 patients. In total Ahmed Al-Hazzouri billed 437,342 services in 158 codes, and Medicare paid $7.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-09.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 51,510 | 46 | $0.27 | $14K |
| J1756 Injection, iron sucrose, 1 mg | Office | 42,000 | 86 | $0.17 | $7,281 |
| J9299 Injection, nivolumab, 1 mg | Office | 38,680 | 19 | $24.55 | $950K |
| J0896 Injection, luspatercept-aamt, 0.25 mg | Office | 29,121 | 13 | $31.54 | $918K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 26,200 | 28 | $44.76 | $1.2M |
| J9267 Injection, paclitaxel, 1 mg | Office | 12,504 | 17 | $0.08 | $1,013 |
| J0185 Injection, aprepitant, 1 mg | Office | 12,220 | 27 | $1.34 | $16K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 11,400 | 15 | $0.22 | $2,478 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 11,280 | 59 | $6.35 | $72K |
| J0897 Injection, denosumab, 1 mg | Office | 7,080 | 74 | $20.31 | $144K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 6,300 | 16 | $2.28 | $14K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 5,100 | 16 | $36.15 | $184K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,846 | 74 | $0.09 | $344 |
| 85025 Blood Count | Office | 3,415 | 1,062 | $7.61 | $26K |
| 36415 Venipuncture Blood Collection | Office | 3,213 | 1,121 | $8.65 | $28K |
By year: 2022 $8.4M for 511,992 services; 2023 $7.2M for 458,840 services; 2024 $7.4M for 437,342 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,415 | 1,062 | $7.61 | $26K |
| 36415 Venipuncture Blood Collection | 3,213 | 1,121 | $8.65 | $28K |
| 85610 Clinical Chemistry | 62 | 20 | $4.20 | $260 |
| 81003 Clinical Chemistry | 52 | 22 | $2.20 | $114 |
Medicare prescription drug claims, 2024
In 2024, the drug Ahmed Al-Hazzouri prescribed most often to Medicare patients was Anastrozole, with 375 prescriptions and refills. In total Ahmed Al-Hazzouri wrote 3,812 Medicare prescriptions that cost $12.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 375 | 1,047 | 122 | $7,709 |
| Prednisone Generic | 192 | 244 | 98 | $872 |
| Revlimid Lenalidomide | 171 | 171 | 20 | $2.8M |
| Ondansetron Hcl Generic | 163 | 165 | 109 | $5,419 |
| Omeprazole Generic | 159 | 301 | 64 | $1,283 |
| Eliquis Apixaban | 142 | 226 | 47 | $129K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 129 | 131 | 44 | $3,362 |
| Gabapentin Generic | 125 | 208 | 49 | $1,075 |
| Acyclovir Generic | 114 | 176 | 23 | $1,432 |
| Prochlorperazine Maleate Generic | 94 | 94 | 73 | $1,243 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 87 | 87 | 20 | $2,000 |
| Imbruvica Ibrutinib | 83 | 83 | Under 11 | $1.2M |
| Abiraterone Acetate Generic | 79 | 87 | 15 | $161K |
| Temazepam Generic | 75 | 75 | 16 | $407 |
| Hydroxyurea Generic | 71 | 182 | 27 | $1,649 |
Brand drugs: 986 claims; generic drugs: 2,826 claims; opioid claims: 382.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ahmed Al-Hazzouri $1,744 ($1,744 in general payments such as food, travel and fees) from 26 companies. The largest payer was Pfizer Inc. with $227.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 12 | $227 |
| Celgene Corporation BMY | 7 | $150 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $139 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $117 |
| Astellas Pharma US Inc 4503.T | 5 | $110 |
| Exelixis Inc. EXEL | 5 | $94.99 |
| Kite Pharma, Inc. GILD | 3 | $84.47 |
| BeOne Medicines USA, Inc. ONC | 3 | $78.67 |
| EMD Serono, Inc. MRK.DE | 4 | $76.57 |
| GlaxoSmithKline, LLC. GSK | 4 | $74.77 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.